ALTRIA GROUP, INC. Quarterly Report for Q3 Ended Sep 30, 2020

Summary

Altria Group, Inc. (MO) reported its third-quarter 2020 financial results, indicating a notable increase in net revenues driven by pricing actions in its smokeable products segment. Despite a decline in cigarette shipment volumes, the company maintained its market share in the premium cigarette category, supported by strong performance from Marlboro. The oral tobacco products segment also showed revenue growth, benefiting from pricing and volume increases, though overall segment retail share saw a slight decrease due to the growth of oral nicotine pouches. The company experienced a significant negative impact from its investment in JUUL, recording a $2.6 billion impairment charge, reflecting continued challenges in the e-vapor market. This impairment, coupled with other special items, led to a net loss for the quarter, but adjusted earnings per share remained positive, demonstrating resilience in core operations. Altria also highlighted its continued commitment to returning capital to shareholders through dividends, announcing an increase in its quarterly dividend rate. The company's financial health remains supported by strong operating cash flows, although its balance sheet reflects substantial long-term debt. Altria's significant investments in ABI and Cronos are being closely monitored for potential impairment, with current assessments indicating temporary declines in value. The company is navigating a complex regulatory environment for tobacco and nicotine products, which presents ongoing risks and uncertainties. Management is focused on adapting to evolving consumer preferences and regulatory landscapes while maintaining operational efficiency and financial flexibility.

Key Highlights

• 1Net revenues increased by 3.9% to $19.8 billion for the first nine months of 2020, driven by higher pricing in the smokeable products segment and growth in oral tobacco products.
• 2The company recorded a significant $2.6 billion impairment charge related to its JUUL equity investment, reflecting continued deterioration in JUUL's business prospects.
• 3Diluted EPS for the nine months ended September 30, 2020, was $1.36, a substantial increase from $0.27 in the prior year, primarily due to the JUUL impairment charge in the prior year not recurring at the same level.
• 4Adjusted diluted EPS for the nine months of 2020 was $3.37, an increase of 5.6% compared to $3.19 in the prior year, demonstrating underlying operational strength.
• 5Altria announced a 2.4% increase in its quarterly dividend rate to $0.86 per share, with an annualized rate of $3.44, reaffirming its commitment to shareholder returns.
• 6Cash provided by operating activities increased to $5.84 billion for the first nine months of 2020, up from $5.27 billion in the same period of 2019, indicating robust cash generation.
• 7The company's balance sheet shows total assets of $46.65 billion and total liabilities of $43.38 billion as of September 30, 2020.

Frequently Asked Questions